No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer

Cancer Lett. 2006 Aug 28;240(2):195-7. doi: 10.1016/j.canlet.2005.09.003. Epub 2005 Oct 18.


A functional T to G germline polymorphism in the promoter region of MDM2 (SNP309) has been reported to profoundly accelerate tumor formation suggesting that it may also represent a powerful cancer predisposing allele. To investigate the role of SNP309 in cancer predisposition we undertook a case-control study of this polymorphism among 351 women diagnosed with breast cancer, 302 women diagnosed with ovarian and 258 female controls from a British population. The GG genotype was not associated with either breast cancer (OR 1.04, 95% CI 0.67-1.60) or ovarian cancer (OR 0.86, 95% CI 0.53-1.37). This study has found no evidence that the GG genotype of the MDM2 SNP309 polymorphism is associated with early onset or familial breast cancer or with ovarian cancer.

Publication types

  • Comparative Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / genetics*
  • Breast Neoplasms / genetics*
  • Case-Control Studies
  • Female
  • Humans
  • Middle Aged
  • Ovarian Neoplasms / genetics*
  • Polymorphism, Single Nucleotide*
  • Proto-Oncogene Proteins c-mdm2 / genetics*
  • Risk Factors


  • Biomarkers, Tumor
  • MDM2 protein, human
  • Proto-Oncogene Proteins c-mdm2